國新健康(000503.SZ):控股股東及其一致行動人擬1億元-2億元增持公司股份
格隆匯4月8日丨國新健康(000503.SZ)公佈,基於對公司未來高質量發展的信心以及公司價值的認可,同時為提升投資者信心,穩定公司股價,維護中小股東利益,公司控股股東中海恒實業發展有限公司(以下簡稱"中海恒")及其一致行動人國新發展投資管理有限公司(以下簡稱"國新發展")計劃在未來6個月內,通過集中競價等深圳證券交易所允許的方式增持公司股份,擬增持金額不低於人民幣1億元,不超過人民幣2億元,且不排除上述增持目標完成後繼續通過合法合規的方式增持公司股票,資金來源為中海恒和國新發展的自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.